top of page
Revolutionizing Diagnostics:
Imaging for Eye and Brain Health
Earlier, Smarter Detection for Alzheimer's
& Degenerative Eye Diseases
Standard fundus photography captures surface-level structure.
Optina captures biochemical nuance.
Our hyperspectral platform captures rich retinal data in seconds, uncovering microvascular shifts long before irreversible damage occurs.
High-Dimensional Hyperspectral Data
Captures a continuous spectral signature of retinal layers, uncovering subtle optical signatures invisible to standard white-light and monochromatic systems.
AI-Powered Biomarker Analysis
Proprietary machine learning models process complex spectral profiles against validated clinical datasets, delivering objective, reproducible diagnostic signals.
Non-Invasive, Rapid Patient Workflow
Designed for standard clinical environments—rapid capture, zero invasive contrast dyes, and immediate integration into diagnostic workflows.
OPTINA'S COMMERCIAL MOAT
FDA Cleared – 510k
Clinically validated for capturing, displaying, and storing multi-wavelength retinal images - allows immediate integration into standard practice.
Reimbursement Ready
Existing ophthalmic CPT codes for friction-free clinic adoption.
FDA Breakthrough Device
Designated for accelerated impact in early detection of Alzheimer's.
IP Moat: 12 Global Patent Families
Comprehensive protection across proprietary optical systems and spectral AI.
What is Hyperspectral Imaging?
Data-rich image reveals key disease indicators invisible to current imaging modalities
Captures spatial and spectral data Hyperspectral Imaging
across 90 individual color bands in a 1-second, non-invasive scan
Increasing wavelengths sample deeper structures of the fundus
Unique Molecular, Functional and Anatomical Information
bottom of page